Cardiovascular implications in the use of PDE5 inhibitor therapy

International Journal of Impotence Research

Volumn 16, Issue SUPPL. 1, 2004, Pages

  Maurice, D H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Cyclic AMP; Cyclic GMP; Phosphodiesterase; Protein kinase; Smooth muscle cells

Indexed keywords

CONTRACTILE PROTEIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V INHIBITOR; SOLUBLE GUANYLATE CYCLASE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CELL FUNCTION; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CARDIOVASCULAR SYSTEM; CYCLIC AMP; CYCLIC GMP; ENDOTHELIUM, VASCULAR; GUANYLATE CYCLASE; HUMANS; MALE; MUSCLE, SMOOTH; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 3342918972     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901210     Document Type: Article

References (12)

1. Liu H, Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 1998; 125: 1501-1510.
2. Palmer D, Maurice DH. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 2000; 58: 247-252.
3. Dunkerley HA et al. Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol Pharmacol 2002; 61: 1033-1040.
4. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671-681.
5. Maurice DH, Haslam RJ. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol 1990; 191: 471-475.
6. Rybalkin SD et al. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 1997; 100: 2611-2621.
7. Rybalkin SD et al. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002; 277: 3310-3317.
8. Tilley DG, Maurice DH. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 2002; 62: 497-506.
9. Kim D et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001; 104: 2338-2343.
10. Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 1997; 323: 371-377.
11. Gustafsson AB, Brunton LL. Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO: role of cGMP-stimulated PDE2. Am J Physiol Cell Physiol 2002; 283: C463-C471.
12. Lugnier C, Keravis T, Eckly-Michel A. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel. J Physiol Pharmacol 1999; 50: 639-652.